KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Payables (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Payables for 17 consecutive years, with $3.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 0.75% to $3.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 billion, a 0.75% decrease, with the full-year FY2025 number at $3.6 billion, down 0.75% from a year prior.
  • Payables was $3.6 billion for Q4 2025 at Bristol Myers Squibb, down from $4.3 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.4 billion in Q2 2025 to a low of $2.6 billion in Q3 2022.
  • A 5-year average of $3.4 billion and a median of $3.2 billion in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: dropped 20.14% in 2022, then skyrocketed 44.68% in 2025.
  • Bristol Myers Squibb's Payables stood at $2.9 billion in 2021, then increased by 3.09% to $3.0 billion in 2022, then increased by 7.2% to $3.3 billion in 2023, then grew by 10.52% to $3.6 billion in 2024, then fell by 0.75% to $3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Payables are $3.6 billion (Q4 2025), $4.3 billion (Q3 2025), and $5.4 billion (Q2 2025).